Literature DB >> 20961201

Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease.

Stephanie Van Biervliet1, Jean-Pierre Van Biervliet, Eddy Robberecht, Armand Christophe.   

Abstract

BACKGROUND: In cystic fibrosis (CF), changes in fatty acid (FA) composition of serum phospholipids (PL) and cell membranes can account, in part, for the inflammatory state of the disease. The severity of the genotype is known to correlate with the degree of FA changes. Liver diseases, such as cholestasis and cirrhosis are also known to influence FA status. Until now, there is no data on the influence of CF related liver disease (CFRLD) on the FA status of CF patients. The aim of this study was to evaluate, whether the presence of CFRLD influences FA status.
METHODS: A fasting blood sample for the determination of serum vitamin E and PL-FA composition was collected from 79 CF patients with stable pulmonary disease and under good control in our CF centre. Patients with CFRLD (n=13) were compared to CF patients with the same severity of genotype (n=66) but without CFRLD.
RESULTS: The CF patients with CFRLD had lower docosahexaenoic acid (DHA, 22:6n-3) and increased docosatetraenoic acid (22:4n-6). There were no significant differences in the precursors of these FAs.
CONCLUSIONS: DHA concentration in patients with CFRLD is decreased more substantially compared with their genotype controls. The presence of CFRLD should be taken into account in future FA studies in CF patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20961201     DOI: 10.1515/CCLM.2010.336

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

1.  Low linoleic and high docosahexaenoic acids in a severe phenotype of transgenic cystic fibrosis mice.

Authors:  Birgitta Strandvik; Wanda K O Neal; Mohamed A Ali; Ulf Hammar
Journal:  Exp Biol Med (Maywood)       Date:  2018-03

Review 2.  Cystic fibrosis-related oxidative stress and intestinal lipid disorders.

Authors:  Marie-Laure Kleme; Emile Levy
Journal:  Antioxid Redox Signal       Date:  2015-01-22       Impact factor: 8.401

3.  Determinants of Serum Glycerophospholipid Fatty Acids in Cystic Fibrosis.

Authors:  Sławomira Drzymała-Czyż; Patrycja Krzyżanowska; Berthold Koletzko; Jan Nowak; Anna Miśkiewicz-Chotnicka; Jerzy A Moczko; Aleksandra Lisowska; Jarosław Walkowiak
Journal:  Int J Mol Sci       Date:  2017-01-18       Impact factor: 5.923

Review 4.  Nutrition in Cystic Fibrosis-Some Notes on the Fat Recommendations.

Authors:  Birgitta Strandvik
Journal:  Nutrients       Date:  2022-02-18       Impact factor: 5.717

5.  Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease.

Authors:  Fares Ayoub; Cesar Trillo-Alvarez; Giuseppe Morelli; Jorge Lascano
Journal:  World J Hepatol       Date:  2018-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.